Published in Biomaterials on March 21, 2009
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Polymers for drug delivery systems. Annu Rev Chem Biomol Eng (2010) 1.66
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Noninvasive optical imaging of nanomedicine biodistribution. ACS Nano (2012) 1.19
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol (2013) 1.19
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm (2011) 1.11
Polymeric conjugates for drug delivery. Chem Mater (2012) 1.06
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc (2014) 0.97
Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv (2012) 0.97
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment. Int J Med Sci (2009) 0.92
Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials (2014) 0.86
Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv (2013) 0.84
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate. Cancer Biother Radiopharm (2011) 0.80
Nanomedicine formulations for combination therapies. Nano Rev (2010) 0.79
Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model. Int J Nanomedicine (2015) 0.79
Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J Control Release (2015) 0.78
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm (2013) 0.78
Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. J Clin Exp Oncol (2015) 0.77
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. J Cancer Ther (2012) 0.77
Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. J Control Release (2016) 0.76
Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549). J Pharm Drug Deliv Res (2015) 0.76
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). Med Chem (Los Angeles) (2013) 0.75
Co-encapsulation of Doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors. Transl Oncol (2014) 0.75
Physico-Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumor-Targeted Drug Delivery. Macromol Biosci (2016) 0.75
Efficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer. Int J Nanomedicine (2017) 0.75
Spatiotemporally and Sequentially-Controlled Drug Release from Polymer Gatekeeper-Hollow Silica Nanoparticles. Sci Rep (2017) 0.75
Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. J Cancer Ther (2015) 0.75
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. J Cancer Res Ther Oncol (2014) 0.75
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. Onco Targets Ther (2017) 0.75
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations. Nanomedicine (Lond) (2016) 0.75
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Des Devel Ther (2016) 0.75
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate. J Control Release (2016) 0.75
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). Chem Biol Drug Des (2016) 0.75
Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids. Int J Mol Sci (2017) 0.75
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Endosomal escape pathways for delivery of biologicals. J Control Release (2010) 2.90
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem (2003) 2.60
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release (2011) 2.37
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 2.25
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Theranostic nanomedicine. Acc Chem Res (2011) 1.84
Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res (2010) 1.83
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood (2003) 1.74
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials (2009) 1.70
Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release (2007) 1.64
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release (2003) 1.63
Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release (2010) 1.63
Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res (2005) 1.62
Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm (2010) 1.60
Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug Chem (2007) 1.56
25th anniversary article: Engineering hydrogels for biofabrication. Adv Mater (2013) 1.54
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res (2003) 1.53
Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov (2006) 1.52
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. J Control Release (2010) 1.49
Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Control Release (2012) 1.48
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
A new concept for interactive radiotherapy planning with multicriteria optimization: first clinical evaluation. Radiother Oncol (2007) 1.45
Hydrogels for protein delivery. Chem Rev (2012) 1.44
Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J (2007) 1.44
Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One (2013) 1.42
Hydrogels as extracellular matrices for skeletal tissue engineering: state-of-the-art and novel application in organ printing. Tissue Eng (2007) 1.42
Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res (2011) 1.42
In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm (2008) 1.41
Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum (2003) 1.39
The effect of photopolymerization on stem cells embedded in hydrogels. Biomaterials (2008) 1.39
MicroRNA expression after ionizing radiation in human endothelial cells. Radiat Oncol (2010) 1.38
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem (2006) 1.37
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res (2008) 1.36
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res (2003) 1.35
Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res (2009) 1.35
Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. Biomacromolecules (2009) 1.33
Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations. J Control Release (2002) 1.30
Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. Biomaterials (2007) 1.30
Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release (2005) 1.30
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev (2013) 1.29
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: synthesis and in vitro gene transfer properties. J Control Release (2006) 1.26
Organ printing: the future of bone regeneration? Trends Biotechnol (2011) 1.26
Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev (2009) 1.26
Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther (2002) 1.25
Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm (2006) 1.25
Synthesis and characterization of hyperbranched polyglycerol hydrogels. Biomaterials (2006) 1.24
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release (2004) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
Personalized nanomedicine. Clin Cancer Res (2012) 1.22
Bioreducible poly(amido amine)s with oligoamine side chains: synthesis, characterization, and structural effects on gene delivery. J Control Release (2007) 1.21
The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol (2010) 1.20
LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res (2012) 1.20
Noninvasive optical imaging of nanomedicine biodistribution. ACS Nano (2012) 1.19
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol (2013) 1.19
Retrospective motion gating in small animal CT of mice and rats. Invest Radiol (2007) 1.18
A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol (2002) 1.18
Nonnatural amino acids for site-specific protein conjugation. Bioconjug Chem (2009) 1.18
Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials (2010) 1.17
How to screen non-viral gene delivery systems in vitro? J Control Release (2011) 1.17
A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s. J Control Release (2005) 1.16
Pulsed in vitro release and in vivo behavior of exploding microcapsules. J Control Release (2009) 1.15
Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem (2006) 1.14
Effects of Na+/H+ exchanger inhibitors on subcellular localisation of endocytic organelles and intracellular dynamics of protein transduction domains HIV-TAT peptide and octaarginine. J Control Release (2006) 1.14
4D-MRI analysis of lung tumor motion in patients with hemidiaphragmatic paralysis. Radiother Oncol (2009) 1.13
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release (2005) 1.13